According to the FDA label, no clinically relevant pharmacokinetic changes occur across the spectrum of renal impairment, including end-stage renal disease, and no dose adjustment is required
Always check tamper-evident features and labeling before use
nausea, fruity breath, confusion) Uncontrolled binge eating Severe anxiety, low mood, or thoughts of self-harm Rapid weight gain with no explanation Your Personal Withdrawal Plan: A Checklist Before Stopping: Discuss timeline with healthcare provider Schedule regular follow-up appointments Plan blood sugar monitoring schedule (if diabetic) Prepare meal plans and grocery lists Identify support systems and resources Set realistic expectations and goals Consider alternative treatment options During Withdrawal: Daily weight tracking (optional, based on personal preference) Blood sugar logs (if diabetic) Appetite and hunger level tracking Mood and energy level notes Physical activity records Medication adherence for other conditions For Long-Term Success: Regular healthcare provider check-ins Sustainable eating pattern establishment Consistent exercise routine Stress management practices Support group participation Realistic goal reassessment Summary Withdrawal from GLP-1 injections is safe when guided by a healthcare professional
Liraglutide (Saxenda) Similar to Semaglutide but daily injections
PBS subsidy details The Pharmaceutical Benefits Scheme (PBS) plays a crucial role in making semaglutide financially accessible to Australian patients
This can affect one side of the mouth (unilateral) or both sides (bilateral), and can be complete (meaning the cleft goes up into the nose) or incomplete
